INTRODUCTION
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of morbidity and mortality worldwide and demands early identification and tailored risk reduction strategies.1 Randomized controlled trials have established the efficacy of certain medication classes, such as statins, in reducing ASCVD events irrespective of baseline lipid values.2 These findings have driven a shift in prescribing practices, emphasizing the importance of personalized risk stratification and management for primary event prevention.3
Assessing an individual's risk for ASCVD involves a comprehensive assessment of multiple comorbid conditions, with the goal of tailoring therapies to reduce their risk.4 A risk calculator, such as the one provided by the American Heart Association, is often used to estimate a patient's ASCVD risk over the course of 10 years, incorporating variables such as age, gender, and the presence of diabetes or hypertension as major components.5 Based on the results, targeted risk reduction interventions, including the prescription of specific medications, are implemented to mitigate the risk of primary ASCVD events.6 To expand on these findings, we conducted a multicenter retrospective cohort study using the TriNetX Research Network to evaluate the risk of ASCVD events among patients with inflammatory skin conditions. Our study was designed based on established ASCVD risk calculators, controlling for comorbidities such as diabetes mellitus, tobacco use, and hypertension, while estimating 10-year ASCVD risk.7 Propensity score matching was employed to account for these comorbidities. We hypothesized that certain inflammatory skin diseases may independently elevate ASCVD risk, irrespective of comorbidities.
We compared outcomes between a cohort of patients with inflammatory skin conditions and a cohort of healthy individuals. To contextualize the ASCVD risk associated with inflammatory skin conditions, we performed a sensitivity
Assessing an individual's risk for ASCVD involves a comprehensive assessment of multiple comorbid conditions, with the goal of tailoring therapies to reduce their risk.4 A risk calculator, such as the one provided by the American Heart Association, is often used to estimate a patient's ASCVD risk over the course of 10 years, incorporating variables such as age, gender, and the presence of diabetes or hypertension as major components.5 Based on the results, targeted risk reduction interventions, including the prescription of specific medications, are implemented to mitigate the risk of primary ASCVD events.6 To expand on these findings, we conducted a multicenter retrospective cohort study using the TriNetX Research Network to evaluate the risk of ASCVD events among patients with inflammatory skin conditions. Our study was designed based on established ASCVD risk calculators, controlling for comorbidities such as diabetes mellitus, tobacco use, and hypertension, while estimating 10-year ASCVD risk.7 Propensity score matching was employed to account for these comorbidities. We hypothesized that certain inflammatory skin diseases may independently elevate ASCVD risk, irrespective of comorbidities.
We compared outcomes between a cohort of patients with inflammatory skin conditions and a cohort of healthy individuals. To contextualize the ASCVD risk associated with inflammatory skin conditions, we performed a sensitivity
